Intravitreal drug administration for treatment of noninfectious uveitis

Table 1 Summary of some intravitreal agents

	Application	Duration of action	Visual acuity	Glaucoma surgery	Cataract surgery
IVTA 4 mg (kenalog)	Injection	3-7 mo[17]	58.3% gained ≥ 2 Snellen lines with a median 40.5-mo follow-up[16]	1%-2%[10]	15%-30%[10]
FA 0.59 mg (retisert)	Surgical implant	30 mo[21]	23% gained ≥ 3 lines after 3 yr[21]	32%-40%[21,23,25]	Nearly 100%[21,23,25]
Dexamethasone 0.7 mg (ozurdex)	Non-surgical implant	4-6 mo[21]	38% gained ≥ 3 lines at 6th month[29]	None[30]	1.3%[30]
MTX 400 μg	Injection	4 mo[21]	38% gained ≥ 2 lines at 3rd month[21]	None[21]	None[21]

IVTA: Intravitreal triamcinolone acetonide; FA: Flucinolone acetonide.